The State Street SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. What ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...

Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Payable Mar 24; for shareholders of record Mar 24; ex-div Mar 24. More on Direxion Daily S&P Biotech Bear 3X ETF LABD: ETF To Benefit From Downturns In The Biotech Industry Seeking Alpha’s Quant ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...